Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Resident, Internal Medicine, Duke University School of Medicine 2007 - 2010
  • M.D., Duke University School of Medicine 2007
• 

  Duke Appointment History

  • Medical Instructor in the Department of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2013 - 2017
• Research
• 

  Selected Grants

  • BCG 3111-305 2019 - 2024
  • ARQ 531 2019 - 2024
  • 017004 TRANSCENT CLL 004 2019 - 2024
  • ME 522 001 2018 - 2023
  • TP-0903-102 2019 - 2023
  • BGB-3111-304 2018 - 2023
  • D15-11094 2018 - 2023
  • UTX-TGR-501 2018 - 2023
  • DFCI Obinutuzumab and Ibrutinib Protocol # 15-283 awarded by Dana Farber Cancer Institute 2017 - 2022
  • Ph 2 Study of TGR-1202 in Patients with CLL 2016 - 2021
  • Multi-Center, Open-Label Study of Ublituximab (TG-1101) in combination with TGR-1202 2016 - 2021
  • Ph 3 of Ublituximab in Combination with TGR-1202 2016 - 2021
  • Phase III study of ACP-196 vs Ibrutinib in High Risk CLL 2016 - 2021
  • A Phase II Study of Ibrutinib in combo with Fludarabine, Cyclophosphamide and Rituximab for young patients with CLL awarded by Dana Farber Cancer Institute 2015 - 2020
  • Phase 3 Study of Ublituximab in combination with Ibrutinib compared to Ibrutinib Alone in CLL pts. 2015 - 2020
  • Gilead GS-US 312 0133 2014 - 2019
  • Screening protocol to determine high risk cytogenetic features in previously treated CLL 2016 - 2017
  • A Phase II Study of PNT2258 in Patients with Richter's Transformation (RT). 2016 - 2017
  • MedImmune CD-ON-CAT-8015-1053 2015 - 2017
  • GS-US-312-0123 2014 - 2017
  • A Phase I Trial of a Bcl-2 inhibitor and a MEK inhibitor for patients with relapsed indolent B-NHL 2014 - 2016
  • Phase 2 GS-US-339-0103 2013 - 2015
• 

  Industry Relationships

  • AbbVie
  • Acerta
  • AstraZeneca
  • DTRM Biopharma
  • Pharmacyclics
  • Roche/Genentech
  • TG Therapeutics
  • Teva Pharmaceuticals
  • beigene
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Davids, Matthew S., Danielle M. Brander, Haesook T. Kim, Svitlana Tyekucheva, Jad Bsat, Alexandra Savell, Jeffrey M. Hellman, et al. “Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial..” Lancet Haematol 6, no. 8 (August 2019): e419–28. https://doi.org/10.1016/S2352-3026(19)30104-8.
       Full Text  Link to Item
    • Weinberg, J Brice, Danielle M. Brander, Dale J. Christensen, and Daphne R. Friedman. “Post-translational regulation could be determine functional differences between SET alpha and beta isoform - Response to Cristóbal et al..” Br J Haematol 186, no. 4 (August 2019). https://doi.org/10.1111/bjh.15934.
       Full Text  Link to Item
    • Roeker, Lindsey E., Christopher P. Fox, Toby A. Eyre, Danielle M. Brander, John N. Allan, Stephen J. Schuster, Chadi Nabhan, et al. “Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice..” Clin Cancer Res 25, no. 14 (July 15, 2019): 4264–70. https://doi.org/10.1158/1078-0432.CCR-19-0361.
       Full Text  Link to Item
    • Mato, Anthony R., Lindsey E. Roeker, Toby A. Eyre, Chadi Nabhan, Nicole Lamanna, Brian T. Hill, Danielle M. Brander, et al. “A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL..” Blood Adv 3, no. 10 (May 28, 2019): 1568–73. https://doi.org/10.1182/bloodadvances.2019000180.
       Full Text  Link to Item
    • Brander, Danielle M., Daphne R. Friedman, Alicia D. Volkheimer, Dale J. Christensen, Laura Z. Rassenti, Thomas J. Kipps, Eross Guadalupe, et al. “SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia..” British Journal of Haematology 184, no. 4 (February 2019): 605–15. https://doi.org/10.1111/bjh.15677.
       Full Text
    • Wierda, William G., John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, et al. “NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019..” J Natl Compr Canc Netw 17, no. 1 (January 2019): 12–20. https://doi.org/10.6004/jnccn.2019.0002.
       Full Text  Link to Item
    • Woyach, Jennifer A., Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M. Booth, Wei Ding, Nancy L. Bartlett, et al. “Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL..” N Engl J Med 379, no. 26 (December 27, 2018): 2517–28. https://doi.org/10.1056/NEJMoa1812836.
       Full Text  Link to Item
    • Mato, Anthony R., Lindsey E. Roeker, John N. Allan, John M. Pagel, Danielle M. Brander, Brian T. Hill, Bruce D. Cheson, et al. “Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial..” Am J Hematol 93, no. 11 (November 2018): 1394–1401. https://doi.org/10.1002/ajh.25261.
       Full Text  Link to Item
    • Mato, Anthony R., Meghan Thompson, John N. Allan, Danielle M. Brander, John M. Pagel, Chaitra S. Ujjani, Brian T. Hill, et al. “Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States..” Haematologica 103, no. 9 (September 2018): 1511–17. https://doi.org/10.3324/haematol.2018.193615.
       Full Text  Link to Item
    • Mato, Anthony R., Jennifer C. Samp, Geneviève Gauthier, Emi Terasawa, and Danielle M. Brander. “Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies..” Cancer Biol Ther 19, no. 7 (July 3, 2018): 636–43. https://doi.org/10.1080/15384047.2018.1449616.
       Full Text  Link to Item
    • Mato, Anthony R., Chadhi Nabhan, Meghan C. Thompson, Nicole Lamanna, Danielle M. Brander, Brian Hill, Christina Howlett, et al. “Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis..” Haematologica 103, no. 5 (May 2018): 874–79. https://doi.org/10.3324/haematol.2017.182907.
       Full Text  Link to Item
    • Burris, Howard A., Ian W. Flinn, Manish R. Patel, Timothy S. Fenske, Changchun Deng, Danielle M. Brander, Martin Gutierrez, et al. “Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study..” Lancet Oncol 19, no. 4 (April 2018): 486–96. https://doi.org/10.1016/S1470-2045(18)30082-2.
       Full Text  Link to Item
    • Thompson, Meghan, Danielle Brander, Chadi Nabhan, and Anthony Mato. “Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review..” Jama Oncol 4, no. 3 (March 1, 2018): 394–400. https://doi.org/10.1001/jamaoncol.2017.2009.
       Full Text  Link to Item
    • Wierda, William G., John C. Byrd, Jeremy S. Abramson, Seema Bhat, Greg Bociek, Danielle Brander, Jennifer Brown, et al. “Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology..” J Natl Compr Canc Netw 15, no. 11 (November 2017): 1414–27. https://doi.org/10.6004/jnccn.2017.0165.
       Full Text  Link to Item
    • Mato, A. R., B. T. Hill, N. Lamanna, P. M. Barr, C. S. Ujjani, D. M. Brander, C. Howlett, et al. “Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients..” Ann Oncol 28, no. 5 (May 1, 2017): 1050–56. https://doi.org/10.1093/annonc/mdx031.
       Full Text  Link to Item
    • Brander, Danielle M. “Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward?.” Br J Haematol 176, no. 3 (February 2017): 337–40. https://doi.org/10.1111/bjh.14446.
       Full Text  Link to Item
    • Seymour, John F., Shuo Ma, Danielle M. Brander, Michael Y. Choi, Jacqueline Barrientos, Matthew S. Davids, Mary Ann Anderson, et al. “Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study..” Lancet Oncol 18, no. 2 (February 2017): 230–40. https://doi.org/10.1016/S1470-2045(17)30012-8.
       Full Text  Link to Item
    • Strati, Paolo, Mark Lanasa, Timothy G. Call, Jose F. Leis, Danielle M. Brander, Betsy R. LaPlant, Adam M. Pettinger, et al. “Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial..” Lancet Haematol 3, no. 9 (September 2016): e407–14. https://doi.org/10.1016/S2352-3026(16)30064-3.
       Full Text  Link to Item
    • Friedman, Daphne R., Mark C. Lanasa, Patricia H. Davis, Sallie D. Allgood, Karen M. Matta, Danielle M. Brander, Youwei Chen, et al. “Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies..” Leuk Lymphoma 55, no. 5 (May 2014): 1067–75. https://doi.org/10.3109/10428194.2013.824080.
       Full Text  Link to Item
    • Brander, Danielle, David Rizzieri, Jon Gockerman, Louis Diehl, Thomas Charles Shea, Carlos Decastro, Joseph O. Moore, and Anne Beaven. “Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma..” Leuk Lymphoma 54, no. 12 (December 2013): 2627–30. https://doi.org/10.3109/10428194.2013.784969.
       Full Text  Link to Item
    • Brander, Danielle M., and Anne W. Beaven. “Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib..” Patient Prefer Adherence 6 (2012): 239–51. https://doi.org/10.2147/PPA.S23241.
       Full Text  Link to Item
    • Bean, Gregory R., Andrew D. Bryson, Patrick G. Pilie, Vanessa Goldenberg, Joseph C. Baker, Catherine Ibarra, Danielle M. U. Brander, et al. “Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF..” Clin Cancer Res 13, no. 22 Pt 1 (November 15, 2007): 6834–41. https://doi.org/10.1158/1078-0432.CCR-07-0407.
       Full Text  Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.